CAPRELSA®( vandetanib )

Drug CAPRELSA® vandetanib Caprelsa Overview This is a summary of the European public assessment report (EPAR) for Caprelsa. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Caprelsa. How is Caprelsa used? […]

ADCETRIS® (brentuximab vedotin)

Drug ADCETRIS® brentuximab vedotin Adcetris Overview Adcetris is a cancer medicine used to treat adults with Hodgkin’s lymphoma (HL, a type of cancer that originates from blood cells in the lymphatic system, a part of the immune system). Adcetris is used when the tumour cells are CD30-positive (when they have a protein called CD30 on […]

COMETRIQ® (cabozantinib)

Drug COMETRIQ® cabozantinib Cometriq Overview This is a summary of the European public assessment report (EPAR) for Cometriq. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Cometriq. For practical information about using Cometriq, […]

INTRON A® (interferon alfa-2b)

Drug INTRON A® interferon alfa-2b intron A Overview This is a summary of the European public assessment report (EPAR) for IntronA. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for IntronA. How is Intron A […]

IMLYGIC® (talimogene laherparepvec)

Drug IMLYGIC® talimogene laherparepvec Imlygic Overview This is a summary of the European public assessment report (EPAR) for Imlygic. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Imlygic. For practical information about using […]

ZELBORAF® (vemurafenib)

Drug ZELBORAF® vemurafenib Zelboraf Overview Zelboraf is a cancer medicine used to treat adults with melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be surgically removed. Zelboraf is only for patients whose melanoma tumour cells have a specific mutation (genetic change) called ‘BRAF V600’. Zelboraf contains […]

MEKINIST® (trametinib)

Drug MEKINIST® trametinib Mekinist Overview Mekinist is a cancer medicine used to treat adults whose cancer cells have a specific genetic mutation (change) in their genes called ‘BRAF V600’. It is used for the treatment of: melanoma (a skin cancer) that has spread or cannot be removed surgically. Mekinist is used on its own or […]

PEMETREXED ACCORD® (pemetrexed)

Drug PEMETREXED ACCORD® pemetrexed Pemetrexed Accord Overview This is a summary of the European public assessment report (EPAR) for Pemetrexed Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pemetrexed Accord. For practical […]

APEALEA® (paclitaxel)

Drug APEALEA® paclitaxel APEALEA Overview Apealea is a cancer medicine used to treat women with cancer of the ovary or surrounding structures (the fallopian tube that connects the ovary to the womb, or the peritoneum, the membrane that lines the abdomen). Apealea is given along with a platinum-based medicine, carboplatin, to patients whose disease responds […]

PAZENIR® (paclitaxel)

Drug PAZENIR® paclitaxel Pazenir Overview Pazenir is used to treat the following cancers in adults: metastatic breast cancer, when the first treatment has stopped working and standard treatment including an ‘anthracycline’ (another type of cancer medicine) is not suitable. ‘Metastatic’ means that the cancer has spread to other parts of the body; non-small cell lung […]